Akeso kept releasing strong late stage trial readouts, and its H1 2026 figures showed higher revenue and a smaller loss than a year earlier. Investors who held Akeso over the past year are down 33.3%, including dividends. If you had committed fresh capital in November 2025 on those bullish expectations and analyst disagreements, what exactly in the public record pointed to this kind of gap between scientific success and shareholder outcome?
Akeso is not the only name tied to this theme. Zero in on 126 healthcare AI stocks and compare how each one is priced.
The Two Stories Investors Were Weighing On Akeso
The shares cost HK$113 at the start of the period, and anyone looking at Akeso then was really choosing between two grounded but very different stories.
The bullish narrative treated HK$169 as a fair value, essentially the price implied if assumptions played out. This view was built on revenue growth of 59.0% and profit margins reaching 40.8% over three years as late stage bispecific antibodies moved through NRDL and global partnerships.
The bearish view used a fair value of HK$88.38 and focused on deep price cuts in China compressing margins. It highlighted concern that reliance on cadonilimab and ivonescimab, plus intense competition, could leave earnings far short of more optimistic scenarios.
What The Evidence Around Akeso Actually Tested
Ivonescimab's Phase III wins in lung and biliary tract cancer, plus new approvals in China, lined up squarely with the bullish Akeso story that late stage assets would clear clinical and regulatory hurdles. The numbers told a tougher tale. Revenue reached C¥1,805.681m and the company still reported a loss of C¥424.22m, so the profitability jump baked into the optimistic case remained unproven. The evidence cut both ways.
The key assumption was not trial success. It was the speed at which high quality oncology data would convert into earnings. For any biotech, it is important to track the shift from loss to profit, watch net margin alongside trial headlines, and check whether new approvals are arriving at price points that can realistically support that move.
What Akeso's Current Price Already Assumes
Akeso trades today at HK$78.9, well below where the earlier debate framed the upside and downside cases. The selected Narrative places its Fair Value above that level, reflecting a view that today's quote already bakes in heavy pricing and cost pressure.
The argument hinges on Akeso turning a wide late stage oncology and autoimmune portfolio into broad, commercially meaningful use across several indications. For that higher figure to be met, a buyer today would need to assume this conversion happens across multiple products, not just one or two flagships.
"The main requirement for Akeso is to convert its broad late stage oncology and autoimmune pipeline, including multiple Phase III programs and recent product approvals, into durable commercial uptake across several cancer and immune disease indications. The current valuation suggests that Akeso's share price already reflects a mix of outcomes in which strong clinical data and new approvals for assets like ivonescimab, cadonilimab and its ADC portfolio could deliver more value than is captured by some traditional metrics such as P/S, while still leaving room for disagreement among analysts on whether the stock fully reflects these assets."
One Narrative disagrees with today's price. → See where this Narrative says Akeso should trade
Akeso And A Different Kind Of Scale
Akeso asks you to think hard about pipelines, pricing and payoffs. One step away, another business faces a related question.
Obesity and diabetes care now lean heavily on powerful hormone based medicines. A different drug maker is trying to stretch that model across tablets and combinations.
The same group is also pushing into cancer, autoimmune disease and brain disorders. Management there wants several drug classes to share the load.
If that effort works, cardiometabolic success could become one pillar among many. The open question is how much breadth really changes risk.
The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 16% above its price
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 9926.HK .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
